Genetics of Cytochrome CYP2D6 and Effects of Codeine and Tramadol on Postoperative Pain Management

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-25

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Codeine is one of the most commonly prescribed opioids in the world. The speed at which our liver metabolizes codeine into morphine depends on an important protein called cytochrome P450 2D6 (CYP2D6). Many people across the world have different CYP2D6 metabolizing speeds. Codeine provides inadequate pain management to those who have slow-metabolizing CYP2D6. In contrast, codeine can be life-threatening to those who have rapidly-metabolizing CYP2D6 because of the abruptly high dose of morphine. By analyzing specific genes, we are able to predict a patient's response to medication, thus drug type and dosing can be tailored according to their genetics. The purpose of this study is to observe if nanopore CYP2D6 DNA genetic sequencing can classify patients according to their CYP2D6 phenotype and thus predict their response to codeine and tramadol. The overall project is to determine the practicality of a genetic survey of CYP2D6 for healthy patients undergoing surgical procedures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PURPOSE: The purpose of this study is to investigate if genetic variants of CYP2D6 are a predictive factor for postoperative pain management with conventional codeine and tramadol pain therapy. With CYP2D6 DNA analysis, we hope to be able to correlate a patients' genetics and their physiological response to conventional codeine and tramadol dosing.

RESEARCH QUESTION: Is CYP2D6 metabolizer status a predictive factor for the effectiveness of postoperative pain management with conventional pain therapy doses of codeine and tramadol?

HYPOTHESIS: Our hypothesis is that patients with known rapid metabolizing CYP2D6 variants will have higher incidences of opioid side effects with conventional opioid dosing. On the other hand, patients with known poor-metabolizing CYP2D6 variants will have inadequate pain management with conventional opioid dosing.

JUSTIFICATION: Understanding the relationship between CYP2D6 variants and conventional opioid dosing in a clinical setting will facilitate future studies that investigate personalized dosing in order to improve pain management and reduce risk of opioid side effects.

OBJECTIVES: The primary objective of this study is to determine the practicality of undertaking a medium-scale genetic survey of CYP2D6 for healthy patients undergoing surgical procedures. Secondary objectives include: investigate the feasibility of characterizing CYP2D6 genetic variants into one of four metabolizer groups, investigate if there is a distinguishable pattern between CYP2D6 metabolizer status and postoperative pain management quality with conventional pain therapy dosages such as codeine and tramadol, investigate if there is a distinguishable pattern between CYP2D6 metabolizer status and the presence of opioid side effects with conventional pain therapy dosages such as codeine and tramadol, to raise awareness of the clinical relevance of CYP2D6 variants on codeine and tramadol metabolism as well as the complications that arise from conventional, non-personalized pain management.

RESEARCH DESIGN: Prospective observational feasibility study of healthy elective surgical patients. Projected enrolment up to 50 participants. All participants receive standardized anesthetic with weight based dosing of opiates. Data collected will include: 2-3 ml blood sample taken prior to surgery under general anesthesia, DNA sequencing and genotype identification, chart review during post-operative care unit stay (PACU), and a survey administered by phone 24 after discharge from the PACU.

STATISTICAL ANALYSIS: Given the exploratory nature of this feasibility study and small convenience sample size, data will be summarized using descriptive statistics for most outcome variables. If possible, nonparametric statistical tests may be performed to look at associations between genetic variant and outcomes and differences between the groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-operative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy surgical patients

Healthy surgical patients who are undergoing surgical procedures with projected moderate postoperative pain.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-55 year and otherwise healthy (ASA 1 or 2)
2. Undergoing an elective outpatient surgical procedure at Royal Columbian Hospital or Eagle Ridge Hospital with projected moderate post-operative pain
3. Surgical procedure that requires general anaesthetic and post-operative pain management routinely managed with either codeine or tramadol by attending surgeon (i.e., ACL repair)
4. Attending surgeon routinely prescribes either tramadol or codeine for post-operative pain management

Exclusion Criteria

1. Pre-existing chronic pain condition
2. Any psychiatric diagnosis, such as depression or anxiety (Lautenbacher et al., 1994)
3. History of substance abuse/dependence
4. Multiple medical comorbidities (a single well-controlled medical comorbidity will not be a contraindication - i.e., controlled hypothyroidism)
5. Allergy, sensitivity, or other contraindication to either codeine or tramadol
6. Regional anesthetic (inclusive either of a major peripheral nerve block or neuraxial anesthetic) planned by attending anesthesiologist)
7. Unable to provide informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Perseus Missirlis

Clinical Instructor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Perseus Missirlis, MSc, MD

Role: PRINCIPAL_INVESTIGATOR

Fraser Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Columbian Hospital

New Westminster, British Columbia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-01422

Identifier Type: -

Identifier Source: org_study_id